| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| inebilizumab | b-lymphocyte surface antigen b4 | NA | Successful target | TTD , DGIDB | Neuromyelitis Optica[MeSHID:D009471] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
29.38 | approved | antibody |
| inebilizumab | b-lymphocyte surface antigen b4 | NA | Successful target | TTD , DGIDB | Neuromyelitis Optica[MeSHID:D009471] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
29.38 | approved | unknown |
| inebilizumab | b-lymphocyte antigen cd19 | biotech | NA | drugbank , DGIDB | Neuromyelitis Optica[MeSHID:D009471] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
29.38 | approved,investigational | binder,antibody |
| inebilizumab | b-lymphocyte antigen cd19 | biotech | NA | drugbank , DGIDB | Neuromyelitis Optica[MeSHID:D009471] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
29.38 | approved,investigational | binder |
| click here to return to the previous page | ||||||||